Chinese Language Podcast: Biokin/BMS Deal, Developments At Pfizer, BlissBio, WuXi Biologics

Latest China Biopharma Moves Discussed

Chengdu-based Biokin has just signed a $8.4bn licensing deal with BMS for an ADC asset, while Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in China. Meanwhile, BlissBio has released new clinical data for its HER2-targeting ADC and shares in WuXi Biologics have plummeted following its latest business updates.

Chinese biotech podcast
audio roundup of latest Chinese biopharma topics • Source: Citeline/Shutterstock

Chinese antibody-drug conjugate developers are making further inroads in global biotech dealmaking, with Chengdu-based Biokine Therapeutics Ltd.’s US subsidiary recently inking a megadeal with Bristol Myers Squibb Company worth up to $8.4bn in total.

On 5 December, Hong Kong-listed WuXi Biologics saw a single-day share price plunge of over 23%, following a business update that revealed a broad set of challenges facing the overall Chinese biotech sector

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia